Education
About Us
Working with TipRanks
Follow Us
Treace Medical Concepts (TMCI)
NASDAQ:TMCI
TMCI Stock Chart & Stats
$2.57
-$0.15(-1.96%)
At close: 4:00 PM EST
$2.57
-$0.15(-1.96%)
Day’s Range― - ―
52-Week Range$2.43 - $10.79
Previous CloseN/A
Volume76.56K
Average Volume (3M)1.11M
Market Cap
$163.76M
Enterprise Value$439.14M
Total Cash (Recent Filing)$57.42M
Total Debt (Recent Filing)$70.37M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Feb 26, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding63,718,075
10 Day Avg. Volume817,108
30 Day Avg. Volume1,111,309
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)4.09
Price to Sales (P/S)2.21
P/FCF Ratio-9.48
Enterprise Value/Market Cap2.68
Enterprise Value/Revenue2.01
Enterprise Value/Gross Profit2.51
Enterprise Value/Ebitda-12.63
Forecast
1Y Price Target
$5.27Price Target Upside105.06% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$211.92M
Bulls Say, Bears Say
Bulls Say
Bears Say
Guidance ReductionTMCI's sudden and sizable guidance reduction to FY25 numbers suggests a massive slowdown in 4Q25.
Product AdoptionPhysicians are not adopting Lapiplasty as quickly, opting for less complex products amidst a weakening macro-environment.
Product Mix ShiftTMCI cases are seeing a product mix-shift to lower ASP products faster than TMCI can recoup the ASP losses on higher-priced Lapiplasty kits.
Treace Medical Concepts News
TMCI FAQ
What was Treace Medical Concepts’s price range in the past 12 months?
Treace Medical Concepts lowest stock price was $2.43 and its highest was $10.79 in the past 12 months.
What is Treace Medical Concepts’s market cap?
Treace Medical Concepts’s market cap is $163.76M.
When is Treace Medical Concepts’s upcoming earnings report date?
Treace Medical Concepts’s upcoming earnings report date is Feb 26, 2026 which is in 67 days.
How were Treace Medical Concepts’s earnings last quarter?
Treace Medical Concepts released its earnings results on Nov 06, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.276 by $0.016.
Is Treace Medical Concepts overvalued?
According to Wall Street analysts Treace Medical Concepts’s price is currently Undervalued.
Does Treace Medical Concepts pay dividends?
Treace Medical Concepts does not currently pay dividends.
What is Treace Medical Concepts’s EPS estimate?
Treace Medical Concepts’s EPS estimate is -0.15.
How many shares outstanding does Treace Medical Concepts have?
Treace Medical Concepts has 63,718,075 shares outstanding.
What happened to Treace Medical Concepts’s price movement after its last earnings report?
Treace Medical Concepts reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.276. Following the earnings report the stock price went down -28.411%.
Which hedge fund is a major shareholder of Treace Medical Concepts?
Currently, no hedge funds are holding shares in TMCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Treace Medical Concepts Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.27 (105.06% Upside)
$5.27 (105.06% Upside)
Blogger Sentiment
Bullish
TMCI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 462.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.75%
12-Months-Change
Fundamentals
Return on Equity
-51.63%
Trailing 12-Months
Asset Growth
-7.67%
Trailing 12-Months
Company Description
Treace Medical Concepts
Treace Medical Concepts, Inc. (TMCI) is a medical device company focused on developing innovative solutions for the orthopedic sector, particularly in the field of bunion correction. The company specializes in advanced surgical technologies and products that enhance surgical outcomes and patient recovery, with a primary emphasis on its proprietary Lapiplasty® procedure, which addresses the underlying causes of bunions. TMCI operates primarily within the orthopedic device market, offering a range of products designed to improve the efficiency and effectiveness of surgical interventions.
TMCI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected both positive and negative aspects. While there was notable revenue growth and improved adjusted EBITDA, challenges such as a revised revenue outlook, pressure on Lapiplasty volumes, and economic impacts on elective procedures were significant.View all TMCI earnings summariesTMCI Stock 12 Month Forecast
Average Price Target
$5.27
▲(105.06% Upside)
Technical Analysis
Ownership Overview
27.42% Insiders
11.85% Mutual Funds
28.64% Other Institutional Investors
23.18% Public Companies and
Individual Investors